Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX
Amneal Pharmaceuticals — Jefferies Global Healthcare Conference 2024
22 slides from Amneal Pharmaceuticals's conference presentation, Jun 5, 2024
Slide 1: Amneal Pharmaceuticals
Amneal Pharmaceuticals Chirag Patel Co-founder, Co-CEO and President Jefferies Healthcare Conference June 5, 2024
Slide 2: Cautionary Statement on Forward Looking Statements
Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements reg
Slide 3: Presentation agenda
Presentation agenda Macro healthcare trends 1 and drug shortages Our strategy and 2 key differentiators 3 Amneal overview Chirag Patel, 4 Growth acceleration Co-Founder, Co-CEO and President 3
Slide 4: Macro trends are accelerating growth in essential medicines
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Macro trends are accelerating growth in essential medicines Macro trend Amneal value proposition Global aging population using Growing portfolio of 280+ medicines across more daily medicines than e
Slide 5: U.S. drug shortages are at a record high
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration U.S. drug shortages are at a record high U.S. Active Drug Shortages by Quarter (per ASHP) • Shortages are at the highest level since tracking began in 2001. About half are injectables. Products in
Slide 6: Amneal Pharmaceuticals – We make healthy possible®
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Amneal Pharmaceuticals – We make healthy possible® • Global, diversified pharmaceutical company that provides access to high-quality, affordable, and essential medicines • Growing portfolio of 280+
Slide 7: Our growth strategy as a diversified pharmaceutical company
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Our growth strategy as a diversified pharmaceutical company Net Revenue Business area Strategy for growth Growth projection(1) LTM Q1 2024 Retail Grow #4 U.S. Generics portfolio of ~240 products wi
Slide 8: Differentiated R&D and manufacturing capabilities
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Differentiated R&D and manufacturing capabilities Best-in-class R&D and manufacturing capabilities Global network of FDA-approved, delivering complex & high-value dosage forms cGMP manufacturing si
Slide 9: Deep pipeline as our wheel of innovation keeps turning
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Deep pipeline as our wheel of innovation keeps turning Robust Generics R&D engine Expanding U.S. biosimilars portfolio Specialty branded pipeline(1) ALYMSYS® Potential Therapeutic Program bevacizum
Slide 10: Continued commitment to quality and compliance
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Continued commitment to quality and compliance Leading quality and compliance track record. Since Amneal’s founding, our facilities (US and India) have been inspected by the FDA 101 times, yielding
Slide 11: Affordable medicines portfolio driving sustainable growth
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Affordable medicines portfolio driving sustainable growth • Diverse portfolio of ~240 retail products shifting Purposeful mix shift towards a more complex portfolio towards complex and high-value m
Slide 12: Expanding our Specialty business with new branded products
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Expanding our Specialty business with new branded products Expected specialty Expect $500M+ Specialty highlights Key brands continue to grow pipeline launches(1) sales by 2027 ($ millions) Therap
Slide 13: Delivering continued double-digit growth in AvKARE
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Delivering continued double-digit growth in AvKARE 17%+ revenue CAGR expected from 2020 to 2025 AvKARE strategic focus areas ($ millions) $650+ • Operates as a contract administrator (wholesaler an
Slide 14: Track record of top & bottom-line growth driven by new products
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Track record of top & bottom-line growth driven by new products (3) Net Revenue Growth Adjusted EBITDA Growth ($ millions) ($ millions) +7%-11% $2,550 - $2,650 +8% $2,394 +23% +6% $2,212 $580 - $62
Slide 15: Key near-term growth drivers
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Key near-term growth drivers Retail & Injectables Naloxone HCl ALYMSYS® IPX203 DHE Autoinjector New Launches Nasal Spray Product type Generics portfolio Complex generics Biosimilar Specialty Specia
Slide 16: Executing on Amneal's four pillars of value creation
1) Macro healthcare trends 2) Our strategy & differentiators 3) Amneal overview 4) Growth acceleration Executing on Amneal’s four pillars of value creation Key Pillar Metric 2019 2023 LTM(2) Q1 2024 Growth projection(3) Increased OSD(1) Gx % of #1 53% 25% 25% <20% of revenue by 2027 diversification
Slide 17: Appendix
amneal We make healthy possible Appendix
Slide 18: Driving innovations to deliver best-in-class affordable medicines
Driving innovations to deliver best-in-class affordable medicines DHE (Migraine & Cluster FYLNETRA® Headache) acquisition (peg-filgrastim) Acquires InterPharm ALYMSYS® New York Injectables India (bevacizumab) K-114 (Hypo- Naloxone HCL thyroidism) Amneal founded Transdermal New Jersey RELEUKO® Nasal
Slide 19: Recent and upcoming growth catalysts across portfolio
Recent and upcoming growth catalysts across portfolio Retail Injectables Biosimilars Specialty International Achieved ✓ Launched: Naloxone nasal spray, ✓ Launched: Ropivacaine (IV bag), ✓ Driving uptake of: Launched: Launched: in 2024 Fluorometholone acetate, Carvedilol ER, PEMRYDI RTUTM(1) 505(b)(2
Slide 20: Building the foundation for international expansion
Building the foundation for international expansion Geography Direct / Partner Strategy and status India Direct • Focusing on hospital, ophthalmics, Expanding local oncology and specialty markets presence • Utilizing local commercial team Europe Partner • Registering select products Orion Corporatio
Slide 21: Reconciliation of net (loss) income to EBITDA and Adjusted EBITDA
Reconciliation of net (loss) income to EBITDA and Adjusted EBITDA Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. 21
Slide 22: Calculation of Last Twelve Months Gross and Net Leverage
Calculation of Last Twelve Months Gross and Net Leverage Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. (1) Refer to the Company's 8-K filed with the SEC on March 1, 2024 for a complete reconcil
Amneal Pharmaceuticals — Jefferies Global Healthcare Conference 2024 on 6ix